Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Gains 7%; BSE HEALTHCARE Index Down 0.1%
Thu, 22 Aug 10:18

VENUS REMEDIES Gains 7%; BSE HEALTHCARE Index Down 0.1%Image source: Eoneren/www.istockphoto.com

VENUS REMEDIES share price has zoomed 7% and is presently trading at Rs 366.6.

Meanwhile, the BSE HEALTHCARE index is at 41,977.1 (down 0.1%).

Among the top gainers in the BSE HEALTHCARE index today are AARTI DRUGS (up 7.6%) and HIKAL CHEMIC (up 3.2%).

GSK Pharma (down 3.0%) and Procter & Gamble Health (down 2.7%) are among the top losers today.

Over the last one year, VENUS REMEDIES has moved up from Rs 239.7 to Rs 366.6, registering a gain of Rs 126.9 (up 52.9%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,021.8 to 41,977.1, registering a gain of 49.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 130.7%), Glenmark Pharma (up 114.5%) and GSK Pharma (up 111.6%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,010.4 (up 0.1%).

The top gainers among the BSE Sensex today are Bharti Airtel (up 1.1%) and Asian Paints (up 0.8%). The most traded stocks in the BSE Sensex are Bharti Airtel and Tata Steel.

In the meantime, NSE Nifty is at 24,813.8 (up 0.2%). Grasim Industries and Tata Consumer Products are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,216.1 to 81,010.4, registering a gain of 15,794.3 points (up 24.2%).

VENUS REMEDIES Financial Update...

VENUS REMEDIES net profit grew 3.4% YoY to Rs 12 million for the quarter ended June 2024, compared to a profit of Rs 12 million a year ago. Net sales rose 14.1% to Rs 1,086 million during the period as against Rs 952 million in April-June 2023.

For the year ended March 2023, VENUS REMEDIES reported 34.8% decrease in net profit to Rs 266 million compared to net profit of Rs 407 million during FY22. Revenue of the company fell 7.4% to Rs 5,555 million during FY23.

The current Price to earnings ratio of VENUS REMEDIES, based on rolling 12 month earnings, stands at 17.2.


Equitymaster requests your view! Post a comment on "VENUS REMEDIES Gains 7%; BSE HEALTHCARE Index Down 0.1%". Click here!